Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.59 USD | +2.58% | +3.25% | -19.29% |
Apr. 29 | Iterum Therapeutics Resubmits New Drug Application to U.S. Food and Drug Administration for Oral Sulopenem | CI |
Mar. 28 | Transcript : Iterum Therapeutics plc, Q4 2023 Earnings Call, Mar 28, 2024 |
Financials (USD)
Sales 2024 * | - | Sales 2025 * | 12.13M | Capitalization | 25.66M |
---|---|---|---|---|---|
Net income 2024 * | -38M | Net income 2025 * | -19M | EV / Sales 2024 * | - |
Net cash position 2024 * | - | Net cash position 2025 * | - | EV / Sales 2025 * | 2.12 x |
P/E ratio 2024 * |
-0.66
x | P/E ratio 2025 * |
-1.5
x | Employees | 14 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 98.5% |
Latest transcript on Iterum Therapeutics plc
1 day | +2.58% | ||
1 week | +3.25% | ||
Current month | +3.92% | ||
1 month | -9.66% | ||
3 months | +0.63% | ||
6 months | +106.49% | ||
Current year | -19.29% |
Managers | Title | Age | Since |
---|---|---|---|
Michael Dunne
FOU | Founder | 64 | 15-10-31 |
Corey N. Fishman
FOU | Founder | 59 | 15-06-23 |
Director of Finance/CFO | 54 | 15-10-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Ron Hunt
CHM | Chairman | 59 | 15-10-31 |
Beth Hecht
BRD | Director/Board Member | 60 | 21-03-11 |
Corey N. Fishman
FOU | Founder | 59 | 15-06-23 |
Date | Price | Change | Volume |
---|---|---|---|
24-05-06 | 1.59 | +2.58% | 94,081 |
24-05-03 | 1.55 | -1.90% | 46,917 |
24-05-02 | 1.58 | -0.63% | 234,319 |
24-05-01 | 1.59 | +3.92% | 238,134 |
24-04-30 | 1.53 | -0.65% | 157,804 |
Delayed Quote Nasdaq, May 06, 2024 at 04:30 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-19.29% | 25.66M | |
+22.81% | 47.9B | |
+46.56% | 41.42B | |
-1.88% | 40.7B | |
-6.20% | 28.92B | |
+11.33% | 25.55B | |
-21.00% | 19.27B | |
-1.43% | 12.15B | |
+30.73% | 12.14B | |
-0.48% | 11.99B |
- Stock Market
- Equities
- ITRM Stock